August 22, 2018
The Central Social Insurance Medical Council, a key health ministry reimbursement panel better known as Chuikyo, on August 22 approved NHI prices for nine drugs for their listing on August 29, including big-name medicines like Imfinzi (durvalumab), Entyvio (vedolizumab), and...read more